Showing 4 posts of 4 posts found.

New data for Pfizer arthritis pill

September 18, 2012
Research and Development, Sales and Marketing JAK, Pfizer, RA, tofacitinib

Pfizer is to release more data for its investigational rheumatoid arthritis (RA) pill tofacitinib which it hopes will demonstrate its …

Pfizer’s RA pill impresses in Phase III

August 1, 2012
Research and Development, Sales and Marketing FDA, JAK, Pfizer, RA

Pfizer’s investigational arthritis drug tofacitinib has beaten methotrexate in a head-to-head study. Tofacitinib, an oral Janus kinase (JAK) inhibitor, is …

Abbott image

Abbott buys into Galapagos’ RA candidate

February 29, 2012
Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF

Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …

Novartis plans Q2 filing for blood cancer drug

March 17, 2011
Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib

Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …

Latest content